mRNA-Based Combination Therapy for Inflammation-Driven Osteoarthritis Induced by Monosodium Iodoacetate

Area of Science:

• Biomedical Engineering
• Molecular Medicine
• Rheumatology

Background:

• Osteoarthritis (OA) is a degenerative joint disease with limited disease-modifying treatments.
• Messenger RNA (mRNA) therapeutics show potential for OA but require effective delivery systems.
• Current OA therapies often fail to address the complex inflammatory and degenerative processes.

Purpose of the Study:

• To evaluate intra-articular mRNA therapy using polyplex nanomicelles in a rat OA model.
• To assess the individual and combined effects of IL-1 receptor antagonist (IL-1Ra) mRNA and RUNX1 mRNA.
• To investigate the potential of dual mRNA therapy for osteoarthritis.

Main Methods:

• Induction of inflammation-driven OA using monosodium iodoacetate (MIA) in rats.
• Intra-articular delivery of therapeutic mRNAs via non-inflammatory polyplex nanomicelles.
• Assessment of synovial inflammation, cartilage integrity, chondrocyte viability, and subchondral bone changes.

Main Results:

• IL-1Ra mRNA significantly reduced synovial inflammation, pain, and swelling.
• RUNX1 mRNA supported chondrocyte viability and cartilage structure.
• Combined IL-1Ra and RUNX1 mRNA therapy demonstrated synergistic chondroprotection and preserved subchondral bone.

Conclusions:

• Effective control of joint inflammation is crucial for RUNX1 mRNA's therapeutic efficacy in OA.
• Dual mRNA therapy targeting inflammation and cartilage homeostasis offers a promising strategy for OA.
• Polyplex nanomicelles provide a viable non-invasive delivery system for OA mRNA therapeutics.